We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Blood Test Helps Physicians Identify Benign Lung Nodules

By LabMedica International staff writers
Posted on 05 Jul 2015
Print article
Image: Histopathology of a benign sub-pleural lung nodule showing spindle cell lesion morphology (Photo courtesy of Aga Khan University Hospital).
Image: Histopathology of a benign sub-pleural lung nodule showing spindle cell lesion morphology (Photo courtesy of Aga Khan University Hospital).
Conservative management of lung nodules, sometimes referred to as watchful waiting, involves repeated computerized tomography (CT) scans over a two-year period to monitor the progress of patients whose nodules are initially deemed likely to be benign.

If the clinician’s initial assessment of the patient's lung nodule is later found to be incorrect, then the cancers are usually discovered early in the follow up period and remain at an early enough stage for therapeutic intervention.

Scientist at the Medical University of South Carolina (Charleston, SC, USA) and their colleagues carried out a retrospective study of 377 patients and sought to describe how pulmonologists typically manage these patients in their standard practice and to estimate the prevalence of cancer.

The findings show a relatively low overall rate of cancer among these nodules (25%) but a high rate of invasive procedures. In the retrospective review 35% of the patients who underwent surgery turned out to have benign nodules. Of the 44% of patients initially deemed at low risk by some models for malignancy nevertheless underwent an invasive procedure suggesting that some pulmonologists may not be adhering to existing guidelines for managing nodules.

The retrospective study was funded by the maker of Xpresys Lung, (Integrated Diagnostic; Seattle, WA, USA), a noninvasive, clinical laboratory-based, molecular blood test service designed to help physicians identify benign lung nodules with high probability. A separate, recent clinical validation study of the laboratory-developed test showed when the test indicates a nodule is likely benign, the result is correct between 84% and 98% of the time, with each nodule receiving an individual score based on its molecular signature.

Albert A. Luderer, PhD, chief executive officer of Integrated Diagnostic, said, “The chart review study suggests many more patients should be put into ‘watchful waiting.’ Xpresys Lung is designed specifically to help pulmonologists evaluate whether to put more of their patients into watchful waiting with confidence. We believe doing so will reduce overtreatment, lower costs and risks, and lessen patient anxiety. Our hope is the use of Xpresys Lung will make it easier for pulmonologists to follow established clinical guidelines.” The study was published on June 18, 2015, in the journal Chest.

Related Links:

Medical University of South Carolina
Integrated Diagnostic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.